Subject: NIH GUIDE - V21(03) 01/24/92 - P3/3
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Fri, 24 Jan 92 09:28 EST

Please post to the NIH Listserver as:
    NIHGUIDE3.920124
 ---------------------------- Text of forwarded message -----------------------
 
$$XID NIHGUIDE 19920124 V21N03 P3O3 ************************************
qualified staff of public health departments and collaborating
agencies, and predoctoral investigators currently enrolled in an
accredited doctoral degree program.  Applications from minority
individuals and women are encouraged.  Non-profit and for-profit
organizations and institutions, governments and their agencies, and
occasionally individuals, are eligible to apply.
 
The only INELIGIBLE applicants are:
 
o  those individuals who are or have previously been a Principal
Investigator on an NCI-funded CANCER CONTROL grant or contract for
more than TWO years;
 
o  previous recipients (Principal Investigators) of a DCPC Small
Grant;
 
o  foreign institutions.
 
MECHANISM OF SUPPORT
 
Support of this program will be through the National Institutes of
Health (NIH) small grant (R03).  Applicants will be responsible for
planning, direction, and execution of the proposed project.  The
anticipated award date is March 1, 1993.  This RFA is a one-time
solicitation.  Small grants are not renewable.
 
FUNDS AVAILABLE
 
Approximately $500,000 in total costs for two years will be committed
to fund applications that are submitted in response to this RFA.
Direct costs maximum is $50,000, and the duration of support is two
years maximum.  It is anticipated that up to seven awards will be
made.  This funding level is dependent on the receipt of a sufficient
number of applications of high scientific merit.  Although this
program is provided for in the financial plans of the NCI, the award
of grants pursuant to this RFA is also contingent upon the
availability of funds for this purpose.
 
RESEARCH OBJECTIVES
 
The Cancer Prevention and Control Research Small Grants Award is
designed to encourage investigators from a variety of academic,
scientific, and public health disciplines to apply their skills to
scientific investigations in the field of human cancer control
intervention research.  The research may occur in a variety of
settings, such as communities, schools, health departments, and work
sites.  These investigators will become part of the new nationwide
group of scientists pursuing cancer control research goals.
 
RESEARCH APPROACHES
 
Within this small grant program, investigators may choose any of the
full range of scientific approaches in their work.  Many studies and
research designs may contribute to the design, implementation or
evaluation of future phase III-V studies, e.g., descriptive baseline
surveys, testing, modification and validation of surveys or program
materials for use in the proposed population groups, and testing of
recruitment or compliance procedures for participants.
 
Investigators must address the specific aims and hypotheses, the
background and significance of the proposed work, results of any
preliminary studies, experimental design and methods including any
relevant theoretical concepts that underlie the research, human
subjects involvement and protection, and relevant literature (see
instructions in the grant application).
 
PROGRAM AREAS OF INTEREST
 
Cancer Control program areas appropriate for HUMAN INTERVENTION
research grant applications include:
 
o  Prevention (chemoprevention, diet and nutrition intervention
studies)
 
o  Screening and early detection, e.g., pilot studies of new methods;
application of the "NCI Guidelines For Early Detection".  In the area
of breast screening and detection, studies of breast self-examination
as a single modality will not be accepted.
 
o  Cancer control sciences (studies to change current behaviors
and/or institute new behaviors or health promotion interventions
effective in reducing incidence, morbidity, or mortality from cancer)
 
o  Smoking prevention and cessation pilot studies targeted at
improving utilization of current technologies in target populations
or organizations are encouraged.  Minor enhancements of existing
technology are not encouraged.
 
o  Applications research in modifying, feasibility testing, and
adopting proven, state-of-the-art intervention programs and
strategies from other research projects (e.g., screening, smoking
prevention) for use in special populations, State and local health
agencies, or other organizational and community settings.
 
In addition, planning, epidemiologic, and survey studies aimed at
developing cancer control operations research and evaluation studies
are appropriate for human intervention research grant applications.
 
o Community oncology (improving the application of patient management
and continuing care research advances into community settings).
 
o  Applied epidemiology studies (using epidemiologic methods to
determine the association between exposure to an INTERVENTION and its
impact on disease) are acceptable within the above program areas.
 
ALTHOUGH THE SPECIFIC STUDY PROPOSED MAY ATTEMPT ONLY TO OBTAIN
PRELIMINARY DATA AND/OR CONDUCT PILOT STUDIES IN SUPPORT OF A FUTURE,
MORE DETAILED STUDY, IT IS IMPORTANT THAT A LONG-TERM HUMAN CANCER
CONTROL HYPOTHESIS AND SUPPORTING SCIENTIFIC JUSTIFICATION BE
PRESENTED.
 
EXCLUSIONS
 
Studies to determine the efficacy of chemotherapy, surgery,
radiotherapy, and other primary treatment interventions are not
considered cancer control research under this RFA.  Other laboratory
animal studies are not allowed.
 
STUDY POPULATIONS
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
APPLICATION PROCEDURES
 
The research grant application form PHS 398 (rev. 10/88 or 9/91) must
be used in applying for these grants.  These forms are available at
most institutional business offices; from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of
Health, Room 449, Westwood Building, 5333 Westbard Avenue, Bethesda,
Maryland 20892, telephone 301/496-7441; and from the NCI Program
Director named below.
 
REVIEW CONSIDERATIONS
 
Applications will be evaluated subject to the following criteria:
 
o  The scientific/technical merit of the research, including
originality, feasibility, adequacy of design, plans for analyses and
evaluation of data, and soundness of the research plan.
 
o  The quality of the Principal Investigator's research training,
intervention experience, and potential for contribution as an
investigator in the field of cancer control intervention research.
 
o  The adequacy of resources and facilities, and the supportive
nature of the research environment.
 
INQUIRIES
 
Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are
welcome.
 
Direct requests for the RFA and inquiries regarding programmatic
issues to:
 
Sherry L. Mills, M.D., M.P.H.
Program Director, Prevention and Control Extramural Research Branch
Division of Cancer Prevention and Control
National Cancer Institute
Executive Plaza North, Room 320
Bethesda, MD  20892
Telephone:  (301) 496-8520
 
Direct inquiries regarding fiscal matters to:
 
Katharine Schulze
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD  20892
 
Telephone:  (301) 496-7800 ext. 16
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.399.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.
 
$$R9 END ************************************************************
 
$$R10 BEGIN AI-92-04 FULL-TEXT **************************************
 
NIAID INSTITUTIONAL TRAINING AWARDS FOR CLINICAL RESEARCH ON THE
ACQUIRED IMMUNODEFICIENCY SYNDROME
 
NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992
 
RFA AVAILABLE:  AI-92-04
 
P.T. 44; K.W. 0720005, 0715008, 0785035
 
National Institute of Allergy and Infectious Diseases
 
Letter of Intent Receipt Date:  February 28, 1992
Application Receipt Date:  April 8, 1992
 
PURPOSE
 
The National Institute of Allergy and Infectious Diseases (NIAID)
announces the availability of a Request for Applications (RFA), NIAID
Institutional Training Awards for Clinical Research on AIDS.  The
purpose of this RFA is to solicit applications from established
programs of excellence at institutions that are able to develop a
clinical research program that provides training opportunities to
outstanding new investigators who have shown an interest in, and
commitment to, clinical research on Human Immunodeficiency Virus
(HIV) disease and the acquired immunodeficiency syndrome (AIDS).
This program will target a variety of disciplines that work with
patient clinical material or other clinical data in clinical
research.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
NIAID Institutional Training Awards for Clinical Research on AIDS, is
related to the priority area of HIV infection.  Potential applicants
may obtain a copy of "Healthy People 2000" (Full report:  Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Only domestic academic, non-profit, private and public institutions
are eligible to apply for this award.  Only U.S. citizens or, non-
citizen nationals, and individuals admitted to the U.S. as Permanent
Residents are eligible to become trainees.  Minority individuals and
women trainees are encouraged.
 
MECHANISM OF SUPPORT
 
Awards for this program will be made as Institutional National
Research Service Awards (NRSA) (T32), and thus are subject to the
eligibility and evaluation criteria developed for that award.
Applicants should carefully review these criteria, a copy of which is
available from the institution's Office of Sponsored Research and
from the National Institutes of Health, Division of Research Grants,
telephone (301) 496-7441.
 
The total project period for applications submitted in response to
the RFA may not exceed five years.  This RFA is a one-time
solicitation.  Future unsolicited competing continuations will
compete with investigator-initiated applications and will be reviewed
according to the customary NIH peer review procedures.
 
FUNDS AVAILABLE
 
The NIAID has set aside $750,000 in total costs for the first year of
this RFA.  The number of awards will be influenced by the
availability of funds, the overall scientific merit of the
applications, and relevance to program goals.  Awards pursuant to
this RFA are contingent on the continuing availability of funds for
this purpose.
 
RESEARCH OBJECTIVES
 
The goals of the NIAID Institutional Training Awards for Clinical
Research on AIDS are to:
 
o  Increase the number of clinical researchers with a broad
background in clinical research methodology working in the field of
HIV disease.
 
o  Provide support to post-doctoral fellows, advanced graduate
students, and physicians for training in disciplines that are
directly relevant to clinical biomedical research on HIV disease.
 
o  Provide a training experience that integrates the range of
disciplines necessary for the conduct of clinical research.
 
o  Provide a training experience in an environment committed to
interdisciplinary collaboration among faculty/investigators active in
the field of HIV research.
 
Programs must include a range of disciplines requisite for the
development of research skills in clinical studies on HIV/AIDS.
These include:  epidemiology, surveillance, natural history and
transmission studies, biostatistics, the theoretical fundamentals of
clinical research design, protocol development, regulatory
requirements, ethical considerations, clinical research execution,
data collection, quality assurance, data management and analyses,
clinical immunology, virology, microbiology, infectious diseases,
molecular biology, pharmacology, biochemistry, scientific writing,
and manuscript preparation.
 
SPECIAL REQUIREMENTS
 
The policy of the NIH and the NIAID is to promote broad and
systematic efforts to recruit women and individuals from minority
groups that are known to be under-represented in biomedical research
as trainees.  Applicants must provide a description of special plans
to recruit individuals from these groups.
 
An annual progress report on the achievements of the clinical
research program must be submitted.  This report must include an
update on the efforts and the success in recruiting under-represented
minorities and women.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by February 28, 1992, a
letter of intent that briefly describes the proposed training
program, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.
 
Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, the
information that it contains is helpful in planning for the review of
applications.  It allows the NIAID staff to estimate the potential
review workload and to avoid possible conflict of interest in the
review.
 
The letter of intent is to be sent to:
 
Evelyn M. Rodriquez, M.D.
Division of AIDS
National Institute of Allergy and Infectious Diseases
Solar Building, Room 2A23
Bethesda, MD  20892
Telephone:  (301) 496-6177
 
APPLICATION PROCEDURES
 
The deadline for receipt of applications is April 8, 1992.
Applications received after this date will be returned without
review.
 
The research grant application form PHS 398 (revised 10/88) must be
used in applying.  The application kit contains special instructions
for preparing NRSA institutional fellowship award applications.  The
PHS 398 forms are available at most institutional business offices
and from the Office of Grants Inquiries, Division of Research Grants,
National Institutes of Health, Room 449, Westwood Building, 5333
Westbard Avenue, Bethesda, MD 20892, telephone (301) 496-7441.
 
INQUIRIES
 
Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are
welcome.
 
Direct requests for the RFA and inquiries regarding programmatic
issues to Dr. Rodriguez at the address listed under LETTER OF INTENT.
 
Direct inquiries regarding fiscal and policy matters to:
 
Ms. Jane Unsworth
Chief, AIDS Grants Management Section
Grants Management Branch
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4C19
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 496-7075
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.856 - Microbiology and Infectious Diseases
Research, and No. 93.885 - Immunology, Allergic and Immunologic
Diseases Research.  Grants are awarded under the authority of the
Public Health Service Act, Title IV, Section 487, and administered
under the PHS grants policies and Federal Regulations, most
specifically 42 CFR Part 66.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
 
$$R10 END ***********************************************************
 
                             ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN PA-92-36 *************************************************
 
NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL DISORDERS:  RESTITUTION
OF FUNCTION
 
NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992
 
PA:  PA-92-36
 
P.T. 34; K.W. 0715140, 1002030, 0710085, 0705070, 0710050, 0715213
 
National Institute of Neurological Disorders and Stroke
 
PURPOSE
 
The National Institute of Neurological Disorders and Stroke (NINDS),
a component of the National Institutes of Health (NIH), invites
research grant applications through this Program Announcement (PA)
for support of research on neurological motor control, motor control
disorders, and the restitution of function.  Applications covering a
broad range of activities in the neurological sciences from basic
research to clinical research are encouraged.  It is expected that
regardless of approach, all studies will be focused on normal and
abnormal performance of the nervous system in regard to motor
control.  This type of solicitation is issued to encourage
investigator-initiated research projects in areas of special
programmatic interest to the NINDS.
 
BACKGROUND
 
The NINDS is the principal NIH component for support of basic and
clinical research on the prevention, diagnosis, treatment, and
rehabilitation of neurological disorders.  Disorders in motor control
occur as sequelae to many neurological and neuromuscular diseases and
disorders.  Understanding these disorders and approaches to
restitution of function in patients with these disorders is difficult
because many elements of the nervous system interact to produce motor
control in healthy individuals.  Motor control involves broad areas
of the central nervous system including the spinal cord, the
cerebellum, and motor areas of the cortex, basal ganglia, and
thalamus among others.  Sensory input is also an important element in
motor control.  In addition, it is being increasingly appreciated
that nerve-muscle interactions and the intrinsic properties of
muscles and tendons may play a significant role in motor control.
The understanding of motor control necessary for appropriate
treatment of its disorders requires a detailed understanding of the
individual elements of motor control systems and, equally, an
understanding of how the different components interact.  This PA is
issued to encourage grant applications that cover a broad range of
motor disorders, areas of the nervous system, and levels of
integration but that share the common focus of motor control and its
disorders.
 
RESEARCH GOALS AND SCOPE
 
This announcement is issued to encourage and foster
investigator-initiated basic, clinical, and applied research on motor
control and its disorders.  Examples of research objectives
appropriate for inclusion in applications responsive to this PA
include:
 
o  Studies of the neurophysiological foundation of motor control;
 
o  Studies of the biomechanics and neuromuscular physiology of motor
control including conscious and automatic control in humans or
animals;
 
o  Studies of the role of sensory systems in motor control;
 
o  Studies of the electrophysiological, neuroendocrine, and
biochemical foundation of motor control;
 
o  Studies of the integration of motor, sensory, and central systems
in gait, postural control, and fine motor control such as hand
movements;
 
o  Studies of the neurological dysfunctions in motor control
associated with cerebellar degeneration, hereditary ataxias,
demyelinating disorders, such as multiple sclerosis, and in
degenerative disorders such as Huntington's and Parkinson's disease;
 
o  Studies of abnormal nervous system functioning after viral
infection, stroke, trauma, toxic insult, or in cerebral palsy and
post-poliomyelitis syndrome;
 
o  Physiologic analysis of basic movement disorder mechanisms and
symptomatology, e.g., chorea, dystonia, rigidity, spasticity, and
tremor;
 
o  Applied research directed at improving or restoring motor control
in neurologically impaired individuals;
 
o  Studies of neurological locomotor abnormalities in AIDS,
neuropathies, atrophies, and other neurological diseases.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This PA,
Neurological Motor and Motor Control Disorders:  Restitution of
Function, is related to the priority area of chronic disabling
conditions.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy
People 2000" (Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC 20402-9325 (telephone 202-783-3238).
 
MECHANISM OF SUPPORT
 
The support mechanisms for this research will be the individual
research grant (RO1), the First Independent Research Support and
Transition (FIRST) Award (R29), Research Career Development Award
(K04), Clinical Investigator Award (K08), and the program project
grant (P01).  The number of awards to be made is dependent upon
receipt of a sufficient number of applications of high scientific
merit and upon availability of funds.
 
GENERAL REQUIREMENTS
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to
include minorities and women in study populations so that research
findings can be of benefit to all persons at risk of the disease,
disorder or condition under study; special emphasis should be placed
on the need for inclusion of minorities and women in studies of
diseases, disorders and conditions which disproportionately affect
them.  This policy is intended to apply to males and females of all
ages.  If women or minorities are excluded or inadequately
represented in clinical research, particularly in proposed
population-based studies, a clear compelling rationale should be
provided.
 
The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information should be included in the form PHS 398
in Section 2, A-D of the Research Plan AND summarized in Section 2,
E, Human Subjects.  Applicants/offerers are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaska
Natives), Asian/Pacific Islanders, Blacks, Hispanics).
 
The rationale for studies on single minority population groups should
be provided.
 
For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.
 
The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.
 
For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.
 
If the required information is not contained within the application,
the application will be returned.
 
Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.
 
All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.
 
APPLICATION PROCEDURE
 
Applications must be submitted on the grant application form PHS 398
(Rev. 10/88, reprinted 9/89) and will be accepted on any of the three
receipt dates for research grant applications, February 1, June 1,
and October 1.
 
Application kits are available at most business and grants/contracts
offices and may be obtained from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, Westwood
Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441.
 
On the first (face) page, item 2, of the application, the word "yes"
must be checked and the title and number of the announcement typed in
the space provided:  NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL
DISORDERS:  RESTITUTION OF FUNCTION, PA-92-36.
 
Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research
Resources may wish to identify the GCRC as a resource for conducting
the proposed research.  In such a case, a letter of agreement from
either the GCRC program director or Principal Investigator must be
included with the application.
 
The original and six copies of the application must be sent or
delivered to:
 
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
REVIEW PROCEDURES
 
Applications will receive institute and initial review group (IRG)
assignment on the basis of established Public Health Service referral
guidelines.  Applications will be reviewed for scientific and
technical merit by an IRG. Following IRG review, the applications
will receive a second-level review by an appropriate Council/Board.
Applications will compete for available funds with all other approved
applications assigned to the institute.
 
REVIEW CRITERIA
 
The standard review criteria will be used to assess the scientific
merit of applications.  The IRG will be reviewing the adequacy of
protection of human subjects, the humane care of animals, and
biosafety conditions.  In clinical research studies, reviewers also
will be evaluating the adequacy of the inclusion of women and
minorities in the study populations.
 
STAFF CONTACT
 
Investigators are encouraged to contact:
 
Dr. William Heetderks
Division of Fundamental Neuroscience
National Institute of Neurological Disorders and Stroke
Federal Building, Room 9l6
Bethesda, MD  20892
Telephone:  (301) 496-5745
 
Dr. A. P. Kerza-Kwiatecki
Division of Demyelinating, Atrophic, and Dementing Disorders
National Institute of Neurological Disorders and Stroke
Federal Building, Room 804
Bethesda, MD  20892
Telephone:  (301) 496-1431
 
Dr. Floyd J. Brinley, Jr.
Division of Convulsive, Developmental, and Neuromuscular Disorders
National Institute of Neurological Disorders and Stroke
Federal Building, Room 816
Bethesda, MD  20892
Telephone:  (301) 496-6541
 
Dr. Patricia A. Grady
Division of Stroke and Trauma
National Institute of Neurological Disorders and Stroke
Federal Building, Room 8A10
Bethesda, MD  20892
Telephone:  (301) 496-4226
 
For fiscal and administrative matters contact:
 
Kathleen Howe
Grants Management Specialist
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
7550 Wisconsin Ave.
Bethesda, MD  20892
Telephone:  (301) 496-9231
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.854 - Biological Basis Research in Neurosciences,
and 93.853 - Clinical Research related to Neurological Disorders.
Grants will be awarded under the authority of the Public Health
Service Act, Title III, Section 301 (Public Law 78-410, as amended;
42 USC 241) and administered under PHS grants policies and Federal
Regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program is
not subject to the intergovernmental review requirements of Executive
Order 12372 or a Health Systems Agency review.
 
$$P1 END ************************************************************
 
$$P2 BEGIN PA-92-37 *************************************************
 
BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANT
 
NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992
 
PA:  PA-92-37
 
P.T. 34; K.W. 0735000, 0780000
 
National Center for Research Resources
 
Application Receipt Date:  March 26, 1992
 
BACKGROUND
 
The National Center for Research Resources (NCRR) is continuing its
competitive Biomedical Research Support (BRS) Shared Instrumentation
Grant (SIG) Program initiated in Fiscal Year 1982.  The program was
established in recognition of the long-standing need in the
biomedical research community to cope with rapid technological
advances in instrumentation and the rapid rate of obsolescence of
existing equipment.  The objective of the program is to make
available to institutions with a high concentration of Public Health
Service (PHS)-supported biomedical investigators research instruments
that can only be justified on a shared-use basis and for which
meritorious research projects are described.
 
An eligible institution may submit more than one application for
different instrumentation for the March 26, 1992, deadline.  However,
if multiple applications are submitted for similar instrumentation
from one or more eligible components of an institution, then
documentation from a high administrative official must be provided,
stating that the multiple applications are a coordinated
institutional resource plan, not an unintended duplication.
 
RESEARCH GOALS AND SCOPE
 
This program is designed to meet the special problems of acquisition
and updating of expensive shared-use instruments that are not
generally available through other PHS mechanisms, such as the
individual research project, program project and center grant
programs, the Biomedical Research Technology Grant Program, or the
BRS Grant Program.  Applications for the development of new
instrumentation will not be considered.
 
ELIGIBILITY
 
The BRS Shared Instrumentation Grant Program is a subprogram of the
BRS Grant Program of the NCRR.  Awards are made under the authority
of the BRS program and are made to institutions only, not to
individuals.  Therefore, eligibility is limited to institutions that
received a BRS grant award in FY 1991.  Awards are contingent on the
availability of funds.
 
MECHANISM OF SUPPORT
 
BRS Shared Instrumentation Grants (S10) provide support for expensive
state-of-the-art instruments utilized in both basic and clinical
research.  Applications are limited to instruments that cost at least
$100,000 per instrument or system.  The maximum award is $400,000.
Types of instrumentation supported include, but are not limited to,
nuclear magnetic resonance systems, electron microscopes, mass
spectrometers, protein sequencer/amino acid analyzers, and cell
sorters.  Support will not be provided for general purpose equipment
or purely instructional equipment.  Applications for "stand alone"
computer systems will only be considered if the instrument is solely
dedicated to the research needs of a broad community of PHS-supported
investigators.
 
Awards will be made for the direct costs of the acquisition of new,
or the updating of existing, research instruments.  The institution
must meet those costs (not covered in the purchase price) required to
place the instrumentation in operational order as well as the
maintenance, support personnel, and service costs associated with
maximum utilization of the instrument.  There is no upper limit on
the cost of the instrument, but the maximum award is $400,000.
Grants will be awarded for a period of one year and are not
renewable.  Supplemental applications will not be accepted.  The
program does not provide indirect costs or support for construction
or alterations and renovations.  Cost sharing is not required.  If
the amount of funds requested does not cover the total cost of the
instrument, the application must describe the proposed sources(s) of
funding for the balance of the cost of the instrument.  Documentation
of the availability of the remainder of the funding, signed by an
appropriate institutional official, must be presented to NCRR prior
to the issuance of an award.  Requests for a multiple instruments
purchase totalling over $400,000 must specify and justify which
instrument(s) should be supported within the $400,000 ceiling.
 
Applicants proposing the direct purchase of an instrument that the
institution has secured or is planning to secure via a leasing
agreement are strongly encouraged to consult with the institutional
sponsored projects office regarding applicable PHS policy prior to
executing the leasing agreement.  If the leasing agreement was
executed more than one year prior to submission of the SIG
application, the applicant must provide strong justification for the
requested Federal funds.  Further, the instrument must be considered
state-of-the-art at the time of submission of the SIG application.
 
A major user group of three or more investigators must be identified.
A minimum of three major users must have PHS peer-reviewed research
support at the time of the award; 50 percent of these grants must
have been awarded by the NIH.  The application must show a clear need
for the instrumentation by projects supported by multiple PHS
research awards and demonstrate that these projects will require at
least 75 percent of the total usage of the instrument.  Major users
can be individual researchers, or a group of investigators within the
same department or from several departments at the applicant
institution.  PHS extramural awardees from other institutions may
also be included.
 
If the major user group does not require total usage of the
instrument, access to the instrument may be made available to other
users upon the advice of the internal advisory committee.  These
users need not be PHS awardees, but priority must be given to
PHS-supported scientists engaged in biomedical/behavioral research.
 
ADMINISTRATIVE ARRANGEMENTS
 
Each applicant institution must propose a Principal Investigator who
will assume administrative/scientific oversight responsibility for
the instrumentation requested.  An internal advisory committee to
assist in this responsibility must also be utilized.  The Principal
Investigator and the advisory group are responsible for the
development of guidelines for shared use of the instrument, for
preparation of all reports required by the NIH, for relocation of the
instrument within the grantee institution if the major user group is
significantly altered, and for continued support for the maximum
utilization and maintenance of the instrument in the post-award
period.
 
A plan must be proposed for the day-to-day management of the
instrument including designation of a qualified individual to
supervise the operation of the instrument and to provide technical
expertise to the users.  Specific plans for sharing arrangements and
for monitoring the use of the instrument must be described.
 
If a grant award is made, a final progress report will be required
that describes the use of the instrument, a list of all users, and
the value of the instrumentation to the research of the major users
and to the institution as a whole.  This report is due within 90 days
following the end of the project period.
 
REVIEW PROCEDURES AND CRITERIA
 
Applications are reviewed by specially convened initial review groups
of the Division of Research Grants (DRG) for scientific and technical
merit and for program considerations by the National Advisory
Research Resources Council (NARRC) of the NCRR.  Approximately half
of the applications will be reviewed at the September 1992 NARRC
meeting and the remainder at the NARRC meeting in February 1993.
Funding decisions on all applications received for the March 26,
1992, deadline will not be made until the program receives an
appropriation for FY 1993.  The Council date will not affect funding
decisions.  The earliest award date will be February 1993.
 
Criteria for review of applications include:
 
o  The extent to which an award for the specific instrument would
meet the scientific needs and enhance the planned research endeavors
of the major users by providing an instrument that is unavailable or
to which availability is highly limited.
 
o  The availability and commitment of the appropriate technical
expertise within the major user group or the institution for use of
the instrumentation.
 
o  The adequacy of the organizational plan and the internal advisory
committee for administration of the grant including sharing
arrangements for use of the instrument.
 
o  The institutional commitment for continued support of the
utilization and maintenance of the instrument.
 
o  The benefit of the proposed instrument to the overall research
community it will serve.
 
APPLICATION PROCEDURES
 
Copies of a more detailed announcement are being mailed to Program
Directors of BRS grants and to sponsored program offices at all
institutions currently receiving BRS grants.  Interested
investigators must obtain the complete announcement prior to
preparing an application.
 
Applications must be submitted on the grant application form PHS 398
(rev. 10/88, reprinted 9/89).  Application kits are available at most
institutional business offices and from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of
Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone
(301) 496-7441.  The title and number of the announcement must be
typed in Section 2 on the face page of the application.
 
Applications must be received by March 26, 1992.  Applications
received after this date will not be accepted for review in this
competition and will be returned to the applicant.  The original and
four copies must be sent
to:
 
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
If appendix material is submitted, five collated sets must be
included with the application package.  Identify each of the five
sets with the name of the Principal Investigator and the project
title.  This material will not be routinely duplicated and will be
used in a limited way by members of the initial review group.
 
Two copies of the application and one copy of any appendix material
must also be addressed to:
 
Biomedical Research Support Program
National Center for Research Resources
National Institutes of Health
Westwood Building, Room 10A11
5333 Westbard Avenue
Bethesda, MD  20892
 
INQUIRIES
 
Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.
 
Direct inquiries regarding programmatic issues to:
 
Marjorie A. Tingle, Ph.D.
Director, Biomedical Research Support Program
National Center for Research Resources
Westwood Building, Room 10A11
Bethesda, MD  20892
Telephone: (301) 496-6743
 
Direct inquiries regarding fiscal matters to:
 
Ms. Mary V. Niemiec
Office of Grants and Contracts Management
National Center for Research Resources
Westwood Building, Room 849
Bethesda, MD  20892
Telephone:  (301) 496-9840
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance Number 93.337, Biomedical Research Support.  Awards will
be made under authorization of the Public Health Service Act, Title
III, Part A, (Public Law 78-410, as amended by Public Law 99-158, 42
USC 241) and administered under PHS grants policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.
 
$$P2 END ************************************************************
 
                                   ERRATUM
 
$$E1 BEGIN R1 19920110 APPEND RFA NIH-NINDS-92-03 BOTH *****************
 
PREPARATION AND DELIVERY OF HOMOGENEOUS CERAMIDETRIHEXOSIDASE
 
NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992
 
RFP AVAILABLE:  NIH-NINDS-92-03
 
P.T. 34; K.W. 0780005, 0760080, 0760013
 
National Institute of Neurological Disorders and Stroke
 
This erratum is to correct the notice of availability of RFP
NIH-NINDS-92-03 that was published in the NIH Guide for Grants and
Contracts on January 10, 1992, Vol. 21, No. 1.  The following
information is deleted:  "At the time of proposal submission, the
offeror's facilities shall meet Food and Drug Administration
standards in accordance with the Current Good Manufacturing
Practices.  Non-compliance with the above requirement shall
immediately render the proposal technically unacceptable without the
consideration of other evaluation criteria."  In lieu of the above,
the following is incorporated:  "The offeror's facilities shall meet
Food and Drug Administration standards in accordance with the Current
Good Manufacturing Practices at the time of submission of a Best and
Final Offer."
 
This is not a Request for Proposals (RFP).  To receive a copy of the
RFP, submit a written request to the following address and supply two
self-addressed mailing labels.  All responsible sources shall be
considered by the agency.  The RFP will be issued on or about January
28, 1992 (revised) with proposals due on March 27, 1992 (revised).
 
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological Disorders and Stroke, NIH
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD  20892
 
Attention:  RFP No. NIH-NINDS-92-03
 
$$E1 END ************************************************************
 
$$E2 BEGIN P3 19920110 APPEND PA-92-28 BOTH ****************************
 
ACADEMIC RESEARCH ENHANCEMENT AWARD
 
PA-92-28
 
P.T. 34; K.W. 0710030, 0404000, 1014006
 
National Institutes of Health
 
Application Receipt Date:  June 19, 1992
 
This announcement, which was published in the NIH Guide for Grants
and Contracts on January 10, 1992, Vol. 21, No. 1, contained an error
in the application receipt date.  The correct receipt date is June
19, 1992.
 
$$E2 END ************************************************************